Markets

Fate Therapeutics prices IPO at $6, at low end of the revised range

An image of a person holding up a graph
Credit: Shutterstock photo

Fate Therapeutics, an early clinical-stage biotech developing stem cell treatments for orphan diseases, raised $40 million by offering 6.7 million shares at $6, the low end of the revised range of $6 to $8. The company had initially filed to offer 4.0 million shares at a range of $14 to $16, before cutting the deal size 22% on Monday morning. Fate Therapeutics plans to list on the NASDAQ under the symbol FATE. Cowen & Company and BMO Capital Markets acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

FATE

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More